Cpx-351
Myelodysplastic Syndrome With Excess Blasts-2
Fred Hutchinson Cancer CenterPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Myelodysplastic Syndrome With Excess Blasts-2 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Sumithira Vasu | Phase 2 | BB |
Gilteritinib Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 | BB |
Cytosin-Arabinosid Sumithira Vasu | Phase 2 | BB |
Thiotepa Fred Hutchinson Cancer Center | Phase 2 | B |
Midostaurin Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 3 | B |
View all 29 →
Same molecule, other indications
Cpx-351 is also rated in:
therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
BB
Indicative ·
67 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →